AffPaysInc.i
Merge
Accueil
Racine
Merge
Exploration
Accueil
Racine
Accueil
Racine

Serveur d'exploration Tocilizumab - Merge (Accueil)

Index « AffPaysInc.i » - entrée « and »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
an IBM Company < and < b Department of General Medicine.  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 15.
Ident.Authors (with country if any)Title
000C66 (2019) Rosalie M. Sterner [États-Unis] ; Reona Sakemura ; Michelle J. Cox ; Nan Yang ; Roman H. Khadka ; Cynthia L. Forsman ; Michael J. Hansen ; Fang Jin ; Katayoun Ayasoufi ; Mehrdad Hefazi ; Kendall J. Schick ; Denise K. Walters ; Omar Ahmed [États-Unis] ; Dale Chappell [États-Unis] ; Tarek Sahmoud [États-Unis] ; Cameron Durrant [États-Unis] ; Wendy K. Nevala ; Mrinal M. Patnaik ; Larry R. Pease ; Karen E. Hedin ; Neil E. Kay ; Aaron J. Johnson ; Saad S. KenderianGM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts.
001173 (2018) Kazuya Sakai ; Takeshi Maeda ; Akira Kuriyama ; Noriaki Shimada ; Kenji Notohara [Japon] ; Yasunori UedaTAFRO syndrome successfully treated with tocilizumab: A case report and systematic review.
001579 (2017) Bénédicte Watelet [France] ; Maxime Samson ; Hubert De Boysson [France] ; Boris Bienvenu [France]Treatment of giant-cell arteritis, a literature review.
001607 (2017) Nadia K. Rafiq [Éthiopie] ; Khalid Hussain [Royaume-Uni] ; Paul A. BroganTocilizumab for the Treatment of SLC29A3 Mutation Positive PHID Syndrome.
001630 (2017) Shoichi Kaneshiro [Japon] ; Kosuke Ebina [Japon] ; Makoto Hirao [Japon] ; Hideki Tsuboi [Japon] ; Masataka Nishikawa [Japon] ; Akihide Nampei [Japon] ; Yoshio Nagayama [Japon] ; Koichiro Takahi ; Takaaki Noguchi [Japon] ; Hajime Owaki [Japon] ; Jun Hashimoto [Japon] ; Hideki Yoshikawa [Japon]The efficacy and safety of additional administration of tacrolimus in patients with rheumatoid arthritis who showed an inadequate response to tocilizumab.
001706 (2017) Takayuki Katsuyama [Japon] ; Ken-Ei Sada [Japon] ; Minglu Yan [Japon] ; Sonia Zeggar [Japon] ; Sumie Hiramatsu [Japon] ; Yoshia Miyawaki [Japon] ; Keiji Ohashi [Japon] ; Michiko Morishita [Japon] ; Haruki Watanabe [Japon] ; Eri Katsuyama [Japon] ; Mariko Takano-Narazaki [Japon] ; Noriko Toyota-Tatebe [Japon] ; Katsue Sunahori-Watanabe [Japon] ; Tomoko Kawabata [Japon] ; Kohei Miyake [Japon] ; Toru Kiguchi ; Jun Wada [Japon]Prognostic factors of methotrexate-associated lymphoproliferative disorders associated with rheumatoid arthritis and plausible application of biological agents.
001745 (2017) Mikiya Fujieda [Japon] ; Kazushi Tsuruga ; Tetsuya Sato [Japon] ; Hiroaki Kikuchi [Japon] ; Wataru Tamaki [Japon] ; Masayuki Ishihara [Japon] ; Masaki Yamamoto [Japon] ; Taku Oishi [Japon] ; Hiroshi Tanaka ; Masanori Daibata [Japon]Monitoring of Epstein-Barr virus load and killer T cells in patients with juvenile idiopathic arthritis treated with methotrexate or tocilizumab.
001832 (2017) Naoki Ishiguro [Japon] ; Tatsuya Atsumi [Japon] ; Masayoshi Harigai [Japon] ; Tsuneyo Mimori [Japon] ; Norihiro Nishimoto [Japon] ; Takayuki Sumida [Japon] ; Tsutomu Takeuchi [Japon] ; Yoshiya Tanaka [Japon] ; Ayako Nakasone [Japon] ; Nobuhiro Takagi ; Hisashi Yamanaka [Japon]Effectiveness and safety of tocilizumab in achieving clinical and functional remission, and sustaining efficacy in biologics-naive patients with rheumatoid arthritis: The FIRST Bio study.
001843 (2017) Shunsei Hirohata [Japon] ; Asami Abe [Japon] ; Akira Murasawa [Japon] ; Toshihisa Kanamono ; Tetsuya Tomita [Japon] ; Hideki Yoshikawa [Japon]Differential effects of IL-6 blockade tocilizumab and TNF inhibitors on angiogenesis in synovial tissues from patients with rheumatoid arthritis.
001975 (2016) Jennifer N. Brudno ; James N. Kochenderfer [États-Unis]Toxicities of chimeric antigen receptor T cells: recognition and management.
001B80 (2016) Naoki Iwamoto [Japon] ; Shoichi Fukui [Japon] ; Masataka Umeda [Japon] ; Ayako Nishino [Japon] ; Yoshikazu Nakashima [Japon] ; Takahisa Suzuki [Japon] ; Yoshiro Horai [Japon] ; Fumiaki Nonaka [Japon] ; Akitomo Okada [Japon] ; Tomohiro Koga [Japon] ; Shin-Ya Kawashiri [Japon] ; Keita Fujikawa [Japon] ; Toshiyuki Aramaki ; Kunihiro Ichinose [Japon] ; Yasuko Hirai [Japon] ; Mami Tamai [Japon] ; Hideki Nakamura [Japon] ; Kaoru Terada ; Munetoshi Nakashima [Japon] ; Akinari Mizokami [Japon] ; Tomoki Origuchi [Japon] ; Katsumi Eguchi [Japon] ; Yukitaka Ueki ; Atsushi Kawakami [Japon]Evaluation of switching from intravenous to subcutaneous formulation of tocilizumab in patients with rheumatoid arthritis.
001C36 (2016) Yasuhiko Hirabayashi [Japon] ; Yasuhiko Munakata [Japon] ; Masayuki Miyata [Japon] ; Yukitomo Urata [Japon] ; Koichi Saito [Japon] ; Hiroshi Okuno [Japon] ; Masaaki Yoshida [Japon] ; Takao Kodera [Japon] ; Ryu Watanabe [Japon] ; Seiya Miyamoto [Japon] ; Tomonori Ishii [Japon] ; Shigeshi Nakazawa [Japon] ; Hiromitsu Takemori [Japon] ; Takanobu Ando [Japon] ; Takashi Kanno [Japon] ; Masataka Komagamine [Japon] ; Ichiro Kato [Japon] ; Yuichi Takahashi [Japon] ; Atsushi Komatsuda [Japon] ; Kojiro Endo [Japon] ; Chihiro Murai [Japon] ; Yuya Takakubo [Japon] ; Takao Miura [Japon] ; Yukio Sato [Japon] ; Kazunobu Ichikawa [Japon] ; Tsuneo Konta [Japon] ; Noriyuki Chiba [Japon] ; Tai Muryoi [Japon] ; Hiroko Kobayashi [Japon] ; Hiroshi Fujii [Japon] ; Yukio Sekiguchi [Japon] ; Akira Hatakeyama [Japon] ; Ken Ogura [Japon] ; Hirotake Sakuraba [Japon] ; Tomoyuki Asano [Japon] ; Hiroshi Kanazawa [Japon] ; Eiji Suzuki [Japon] ; Satoshi Takasaki [Japon] ; Kenichi Asakura [Japon] ; Kota Sugisaki [Japon] ; Yoko Suzuki [Japon] ; Michiaki Takagi [Japon] ; Takahiro Nakayama ; Hiroshi Watanabe [Japon] ; Keiki Miura [Japon] ; Yu Mori [Japon]Clinical and structural remission rates increased annually and radiographic progression was continuously inhibited during a 3-year administration of tocilizumab in patients with rheumatoid arthritis: A multi-center, prospective cohort study by the Michinoku Tocilizumab Study Group.
001F31 (2015) Mine Islimye Taskin [Turquie] ; Onur Topcu [Turquie] ; Arzu Yay [Turquie] ; Gulten Erken ; Esra Balcio Lu [Turquie] ; Ertan Adali [Turquie] ; Adnan Adil Hismiogullar [Turquie]Prevention of ovarian hyperstimulation syndrome in a rat model: comparison of the efficacy of tocilizumab with that of ranibizumab, cabergoline, and a gonadotropin-releasing hormone antagonist.
002593 (2014) E. Mahé [France] ; Z. Reguiai ; H. Barthelemy ; N. Quiles-Tsimaratos ; G. Chaby ; C. Girard ; E. Estève ; F. Maccari ; V. Descamps ; J. Schmutz ; E. Begon ; P. Bravard ; H. Maillard ; T. Boyé ; A. Beauchet [France] ; M. SigalEvaluation of risk factors for body weight increment in psoriatic patients on infliximab: a multicentre, cross‐sectional study
004353 (2005) M. Yamamoto ; S. Harada ; M. Ohara ; C. Suzuki ; Y. Naishiro ; H. Yamamoto ; H. Takahashi ; Y. Shinomura ; K. Imai [Japon]Beneficial effects of steroid therapy for Mikulicz's disease

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Merge

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Merge/AffPaysInc.i -k "and" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Merge/AffPaysInc.i  \
                -Sk "and" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Merge/biblio.hfd

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Main
   |étape=   Merge
   |type=    indexItem
   |index=    AffPaysInc.i
   |clé=    and
}}
Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021